Publications by authors named "John Gerecitano"

47Publications

Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

N Engl J Med 2018 Mar;378(12):1107-1120

From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) - all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) - both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne-Bonn, Cologne, Germany (B.E.); St. James's University Hospital, Leeds (P.H.), and F. Hoffmann-La Roche, Welwyn Garden City (M.B., K.H.) - both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) - all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.).

View Article and Find Full Text PDF
March 2018

In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of F-(2S,4R)-4-Fluoroglutamine.

Radiology 2018 05 31;287(2):667-675. Epub 2018 Jan 31.

From the Department of Radiology (M.P.S.D., W.W., J.S.L.), Department of Medicine (J.J.H., J.B., A.M.O., J.J.H., I.K.M., J.F.G., D.P.K.), Radiochemistry and Molecular Imaging Probe Core (H.Z., E.M.B., S.K.L., J.S.L.), and Department of Medical Physics (B.J.B., P.B.Z.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Room S113E, New York, NY 10065; Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, New York, NY (H.Z., K.S., J.S.L.); Department of Radiology, Weill-Cornell Medical College, New York, NY (M.P.S.D., W.W., J.S.L.); Laboratory of Neural Systems, the Rockefeller University, New York, NY (C.P.); Department of Pathology, University of Michigan, Ann Arbor, Mich (S.V.); and Departments of Radiology and Pharmacology, University of Pennsylvania, Philadelphia, Pa (H.F.K.).

View Article and Find Full Text PDF
May 2018

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

J Clin Oncol 2017 Mar 17;35(8):826-833. Epub 2017 Jan 17.

Matthew S. Davids, Dana-Farber Cancer Institute, Boston, MA; Andrew W. Roberts, John F. Seymour, and Mary Ann Anderson, University of Melbourne; Andrew W. Roberts and Mary Ann Anderson, Royal Melbourne Hospital and Eliza Hall Institute of Medical Research; and John F. Seymour, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; John M. Pagel, Swedish Cancer Institute, Seattle, WA; Brad S. Kahl, Washington University Medical School, St Louis, MO; William G. Wierda, University of Texas MD Anderson Cancer Center, Houston, TX; Soham Puvvada, University of Arizona, Tucson, AZ; Thomas J. Kipps, University of California San Diego, San Diego, CA; Ahmed Hamed Salem, Martin Dunbar, Ming Zhu, Jeremy A. Ross, Lori Gressick, Monali Desai, Su Young Kim, Maria Verdugo, Rod A. Humerickhouse, and Gary B. Gordon, AbbVie, Chicago, IL; Ahmed Hamed Salem, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt; Franklin Peale, Genentech, South San Francisco, CA; John F. Gerecitano, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY.

View Article and Find Full Text PDF
March 2017

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors.

J Clin Oncol 2016 12 31;34(34):4142-4150. Epub 2016 Oct 31.

Albiruni R. Abdul Razak and Lee-Anne Stayner, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Morten Mau-Soerensen and Ulrik Lassen, Rigshospitalet, Copenhagen, Denmark; Nashat Y. Gabrail, Gabrail Cancer Institute, Canton, OH; John F. Gerecitano, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, NY; Anthony F. Shields, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Thaddeus J. Unger, Jean R. Saint-Martin, Robert Carlson, Yosef Landesman, Dilara McCauley, Tami Rashal, Mansoor R. Mirza, Michael Kauffman, and Sharon Shacham, Karyopharm Therapeutics, Newton, MA; and Richard Kim and Amit Mahipal, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

View Article and Find Full Text PDF
December 2016

A Positive Prospective Trial of Antibiotic Therapy in Advanced Stage, Non-Bulky Indolent Lymphoma.

Tumor Microenviron Ther 2015 Feb 18;2(1):14-18. Epub 2015 Feb 18.

Memorial Sloan Kettering Cancer Center, Department of Medicine, 1275 York Avenue New York, NY, 10065 USA.

View Article and Find Full Text PDF
February 2015

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

N Engl J Med 2016 Jan 6;374(4):311-22. Epub 2015 Dec 6.

From the Department of Clinical Haematology and the Bone Marrow Transplantation Unit, Royal Melbourne Hospital (A.W.R., M.A.A.), the Division of Cancer and Haematology, Walter and Eliza Hall Institute of Medical Research (A.W.R., M.A.A.), and the Victorian Comprehensive Cancer Centre (A.W.R., J.F.S.), Parkville, VIC, and the University of Melbourne (A.W.R., J.F.S.) and Peter MacCallum Cancer Centre (J.F.S.), Melbourne, VIC - all in Australia; Dana-Farber Cancer Institute, Boston (M.S.D., J.R.B.); the Swedish Medical Center, Seattle (J.M.P.); Washington University, St. Louis (B.S.K.); University of Arizona, Tucson (S.D.P.); Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.F.G.); University of California, San Diego, San Diego (T.J.K.); AbbVie, North Chicago, IL (L.G., S.W., M.D., M.Z., M.B.D., E.C., S.H.E., R.A.H.); and University of Texas M.D. Anderson Cancer Center, Houston (W.G.W.).

View Article and Find Full Text PDF
January 2016

Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions.

Expert Opin Investig Drugs 2014 May 26;23(5):611-28. Epub 2014 Mar 26.

New York University Cancer Institute, NYU Clinical Cancer Center, Division of Hematology/Medical Oncology , NY , USA.

View Article and Find Full Text PDF
May 2014

The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials.

Clin Cancer Res 2012 Oct 23;18(19):5179-87. Epub 2012 Jul 23.

Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article and Find Full Text PDF
October 2012

The future of small molecule inhibitors in lymphoma.

Authors:
John Gerecitano

Curr Oncol Rep 2009 Sep;11(5):378-85

Department of Medicine, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

View Article and Find Full Text PDF
September 2009

Novel small molecules in the treatment of lymphomas.

Cancer Treat Res 2006 ;131:413-60

Memorial Sloan Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, New York, NY, USA.

View Article and Find Full Text PDF
June 2006

Treatment of Burkitt lymphoma in adults.

Expert Rev Anticancer Ther 2006 Mar;6(3):373-81

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. gerecitj@

View Article and Find Full Text PDF
March 2006